| International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM) MV Mateos, S Kumar, MA Dimopoulos, V González-Calle, E Kastritis, ... Blood cancer journal 10 (10), 102, 2020 | 170 | 2020 |
| MYC dysregulation in the progression of multiple myeloma K Misund, N Keane, CK Stein, YW Asmann, G Day, S Welsh, SA Van Wier, ... Leukemia 34 (1), 322-326, 2020 | 139 | 2020 |
| Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma A Medina, N Puig, J Flores-Montero, C Jimenez, ME Sarasquete, ... Blood cancer journal 10 (10), 108, 2020 | 88 | 2020 |
| Recovery of polyclonal immunoglobulins one year after autologous stem cell transplantation as a long-term predictor marker of progression and survival in multiple myeloma V González-Calle, S Cerdá, J Labrador, E Sobejano, B González-Mena, ... haematologica 102 (5), 922, 2017 | 47 | 2017 |
| Curative strategy (GEM-CESAR) for high-risk smoldering myeloma (SMM): carfilzomib, lenalidomide and dexamethasone (KRd) as induction followed by HDT-ASCT, consolidation with … MV Mateos, J Martinez-Lopez, PR Otero, V Gonzalez-Calle, MS Gonzalez, ... Blood 134, 781, 2019 | 44 | 2019 |
| Evaluation of Revised International Staging System (R-ISS) for transplant-eligible multiple myeloma patients V González-Calle, A Slack, N Keane, S Luft, KE Pearce, RP Ketterling, ... Annals of hematology 97, 1453-1462, 2018 | 37 | 2018 |
| 6q deletion in Waldenström macroglobulinaemia negatively affects time to transformation and survival R García‐Sanz, I Dogliotti, GM Zaccaria, EM Ocio, A Rubio, I Murillo, ... British Journal of Haematology 192 (5), 843-852, 2021 | 36 | 2021 |
| Curative strategy for high-risk smoldering myeloma (GEM-CESAR): carfilzomib, lenalidomide and dexamethasone (KRd) as induction followed by HDT-ASCT, consolidation with Krd and … MV Mateos, JM Lopez, P Rodriguez-Otero, EM Ocio, MS Gonzalez, ... Blood 130, 402, 2017 | 35 | 2017 |
| Updated risk stratification model for smoldering multiple myeloma (SMM) incorporating the revised IMWG diagnostic criteria. J San Miguel, MV Mateos, V Gonzalez, MA Dimopoulos, E Kastritis, ... Journal of Clinical Oncology 37 (15_suppl), 8000-8000, 2019 | 33 | 2019 |
| Fractionated initial infusion and booster dose of ARI0002h, a humanised, BCMA-directed CAR T-cell therapy, for patients with relapsed or refractory multiple myeloma (CARTBCMA … A Oliver-Caldés, V González-Calle, V Cabañas, M Español-Rego, ... The Lancet Oncology 24 (8), 913-924, 2023 | 31 | 2023 |
| A multicenter retrospective study of 223 patients with t (14; 16) in multiple myeloma S Goldman‐Mazur, A Jurczyszyn, JJ Castillo, A Waszczuk‐Gajda, ... American journal of hematology 95 (5), 503-509, 2020 | 28 | 2020 |
| Bence Jones proteinuria in smoldering multiple myeloma as a predictor marker of progression to symptomatic multiple myeloma V González-Calle, J Dávila, F Escalante, AG De Coca, C Aguilera, ... Leukemia 30 (10), 2026-2031, 2016 | 28 | 2016 |
| Mass spectrometry vs immunofixation for treatment monitoring in multiple myeloma N Puig, MT Contreras, C Agulló, J Martínez-López, A Oriol, MJ Blanchard, ... Blood advances 6 (11), 3234-3239, 2022 | 25 | 2022 |
| Smoldering multiple myeloma: Who and when to treat MV Mateos, V González-Calle Clinical Lymphoma Myeloma and Leukemia 17 (11), 716-722, 2017 | 22 | 2017 |
| High-risk multiple myeloma: how to treat at diagnosis and relapse? MV Mateos, BP Martínez, V González-Calle Hematology 2021 (1), 30-36, 2021 | 21 | 2021 |
| Molecular profiling of immunoglobulin heavy-chain gene rearrangements unveils new potential prognostic markers for multiple myeloma patients A Medina, C Jiménez, ME Sarasquete, M González, MC Chillón, ... Blood cancer journal 10 (2), 14, 2020 | 19 | 2020 |
| Lenalidomide and dexamethasone with or without clarithromycin in patients with multiple myeloma ineligible for autologous transplant: a randomized trial N Puig, MT Hernández, L Rosiñol, E González, F de Arriba, A Oriol, ... Blood Cancer Journal 11 (5), 101, 2021 | 18 | 2021 |
| Qip-mass spectrometry in high risk smoldering multiple myeloma patients included in the GEM-CESAR trial: comparison with conventional and minimal residual disease IMWG response … N Puig, MV Mateos, T Contreras, B Paiva, MT Cedena, JJ Pérez, I Aires, ... Blood 134, 581, 2019 | 18 | 2019 |
| Monoclonal gammopathy of renal significance (MGRS): Real‐world data on outcomes and prognostic factors A Gozzetti, A Guarnieri, E Zamagni, E Zakharova, D Coriu, M Bittrich, ... American Journal of Hematology 97 (7), 877-884, 2022 | 17 | 2022 |
| MYD88 Mutations: Transforming the Landscape of IgM Monoclonal Gammopathies M Alcoceba, M García-Álvarez, A Medina, R Maldonado, ... International Journal of Molecular Sciences 23 (10), 5570, 2022 | 17 | 2022 |
